• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Survival of patients with advanced metastatic melanoma: The impact of novel therapies.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    531085.pdf
    Size:
    1.196Mb
    Format:
    PDF
    Description:
    From CORE (MUCC)
    Download
    Authors
    Ugurel, S
    Röhmel, J
    Ascierto, P
    Flaherty, K
    Grob, J
    Hauschild, A
    Larkin, J
    Long, G
    Lorigan, Paul C
    McArthur, G
    Ribas, A
    Robert, C
    Schadendorf, D
    Garbe, C
    Show allShow less
    Affiliation
    Department of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen
    Issue Date
    2015-12-17
    
    Metadata
    Show full item record
    Abstract
    The survival of advanced metastatic melanoma has been greatly improved within the past few years. New therapeutic strategies like kinase inhibitors for BRAF-mutant melanoma and immune checkpoint blockers proved to prolong survival times within clinical trials, and many of them have already entered routine clinical use. However, these different treatment modalities have not yet been tested against each other, which complicate therapy decisions. We performed an explorative analysis of survival data from recent clinical trials. Thirty-five Kaplan-Meier survival curves from 17 trials were digitised, re-grouped by matching inclusion criteria and treatment line, and averaged by therapy strategy. Notably, the survival curves grouped by therapy strategy revealed a very high concordance, even if different agents were used. The greatest survival improvement was observed with the combination of BRAF plus MEK inhibitors as well as with Programmed-death-1 (PD1) blockers with or without cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockers, respectively, with these two treatment strategies showing similar survival outcomes. For first-line therapy, averaged survival proportions of patients alive at 12 months were 74.5% with BRAF plus MEK inhibitor treatment versus 71.9% with PD-1 blockade. This explorative comparison shows the kinase inhibitors as similarly effective as immune checkpoint blockers with regard to survival. However, to confirm these first trends for implementation into an individualised treatment of melanoma patients, data from prospective clinical trials comparing the different treatment strategies head-to-head have to be awaited.
    Citation
    Survival of patients with advanced metastatic melanoma: The impact of novel therapies. 2015, 53:125-134 Eur J Cancer
    Journal
    European Journal of Cancer
    URI
    http://hdl.handle.net/10541/594610
    DOI
    10.1016/j.ejca.2015.09.013
    PubMed ID
    26707829
    Type
    Article
    Language
    en
    ISSN
    1879-0852
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.ejca.2015.09.013
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
    • Authors: Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C
    • Issue date: 2017 Sep
    • Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019.
    • Authors: Ugurel S, Röhmel J, Ascierto PA, Becker JC, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Livingstone E, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Zimmer L, Schadendorf D, Garbe C
    • Issue date: 2020 May
    • Upcoming strategies for the treatment of metastatic melanoma.
    • Authors: Spagnolo F, Queirolo P
    • Issue date: 2012 Apr
    • Place des anti-PD1 dans la prise en charge des mélanomes cutanés.
    • Authors: Mateus C, Libenciuc C, Robert C
    • Issue date: 2016 Jun
    • Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
    • Authors: Goldman C, Tchack J, Robinson EM, Han SW, Moran U, Polsky D, Berman RS, Shapiro RL, Ott PA, Osman I, Zhong H, Pavlick AC, Wilson MA
    • Issue date: 2017
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.